BackTable / VI / Topic / Procedure
Renal Ablation
Learn more on the BackTable VI Podcast
BackTable is a knowledge resource for physicians by physicians. Get practical advice on Renal Ablation and how to build your practice by listening to the BackTable VI Podcast, reading exclusing BackTable Articles, and following the work of our Contributors.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Pre-Procedure Prep
Indications
Renal cell carcinoma
• American Urological Association supports thermal ablation for T1a tumors which is <4 cm
• < 4 cm can be curable with one treatment
• T1b tumors: >4 cm but <7 cm - usually requires more probes and/or staging of the procedure
• Stage IV disease of metastasis who are not surgical candidates
Renal cell carcinoma:
• Slow growing tumor: on average, grows ~3 mm/year
• Rare to have metastasis when primary <4 cm
Contraindications
• Life expectancy <12 months
• Uncorrectable coagulopathy
• No safe percutaneous window
• Invasion of renal vein or regional lymph node involvement- advanced stage.
• Active infection
Things to Check
• History and physical
• Labs- creatinine, INR, platelets
• Prior imaging- CT and/or MRI
• Consent for procedure and anesthesia
Renal Ablation Podcasts
Listen to leading physicians discuss renal ablation on the BackTable VI Podcast. Get tips, tricks, and expert guidance from your peers and level up your practice.
Procedure Steps
Thermal Ablation Techniques
• Cryoablation
• RFA
• Microwave
Data suggests RFA and cryoablation are similar in efficacy
Data on microwave is less robust
Cryoablation using combination CT and US guidance described below:
Positioning: prone or decubitus
Perform preliminary CT to confirm lesion position, size and adjacent structures.
Test probes in bowl or test tube of normal saline
Ultrasound Guidance for Initial Probe Positioning
• For many patient's US guidance can be faster and more efficient for placement
• Helps evaluate the tumor in 3-D plane
• If using multiple probes, try and keep probes parallel
Once probes in final position using US guidance, confirm positioning with CT
• Evaluate probe position within the tumor
• Evaluate probe position with regards to adjacent structures: renal pelvis, ureter, lung, diaphragm, bowel, adrenal
• Evaluate ablation zone: 5-10 mm (consider full 10 mm margins if feasible)
• Probes no more than 2 cm apart
Opportunity to use protective maneuvers if needed such as hydrodissection
Ablate
• Cycles may vary with manufacturer
• 10 minute freeze with 8 minute active thaw - 2 cycles
• See cell death at -20° C
• Can visualize "ice ball" during freeze cycle
• Can turn on and off probes during freeze cycles to sculpt ablation zone
Remove probes when temperature reaches 10° C
Ice Ball
• Seen at 0°C
• Approximates ablation zone; does not perfectly delineate lethal ablation zone
• Lethal isoderm is 2-3 mm within the ice ball
Post-Procedure
Complications
• Flu-like symptoms (post-ablation syndrome) - fever, fatigue, myalgia. Manage conservatively with antipyretics. Common
• Hemorrhage
• Bowel injury
• Abscess formation/Infection
• Ureteral injury or stricture
• Genitofemoral nerve: anterolateral surface of psoas
• Lower intercostal nerve
Post-Procedural Care
• Monitor patient for at least 2 hours
• Monitor for pain, bleeding, and adjacent structure injury such as pneumothorax
• Discharge home same day if hemodynamically stable, voiding and tolerating po intake
• Discharge medications: anti-inflammatories, antiemetics, and opioids for breakthrough pain
• Most patients will feel back to baseline within 8-10 days
Follow-Up
• Clinic visits with imaging before clinic
• Surveillance can vary
• Consider CT/MR at 3 and 6 months
• If disease free at 6 months, CT/MR at 12, 18 and 24 months
• If disease free at 24 months, CT/MR at 3, 4 and 5 years
Outcomes
• T1a lesions treated with ablation similar to partial and radical nephrectomy
• > 95% cancer-specific 5 year survival with thermal ablation
• ~90% overall survival at 5 years with thermal ablation
Renal Ablation Demos
Watch video walkthroughs of renal ablation on the BackTable VI expanded content network.
References
[1] Xing M, Kokabi N, Zhang D, Ludwig JM, Kim HS. Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. Radiology. 2018;288(1):81‐90. doi:10.1148/radiol.2018171407
[2] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer. Version 3.2018.
[3] Pierorazio PM, Johnson MH, Patel HD, et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol. 2016;196(4):989‐999. doi:10.1016/j.juro.2016.04.081
[4] Gunn AJ, Gervais DA. Percutaneous ablation of the small renal mass-techniques and outcomes. Semin Intervent Radiol. 2014;31(1):33‐41. doi:10.1055/s-0033-1363841
[5] Uppot RN, Silverman SG, Zagoria RJ, Tuncali K, Childs DD, Gervais DA. Imaging-guided percutaneous ablation of renal cell carcinoma: a primer of how we do it. AJR Am J Roentgenol. 2009;192(6):1558‐1570. doi:10.2214/AJR.09.2582
[6] BackTable, LLC (Producer). (2017, November 1). Ep 15 – Renal Ablation Therapies [Audio podcast]. Retrieved from https://www.backtable.com/shows/vi
Disclaimer: The Materials available on https://www.BackTable.com/ are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.